DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Sorafenib for Hepatopulmonary Syndrome

Information source: University of Pennsylvania
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatopulmonary Syndrome

Intervention: Sorafenib (Drug); Placebo (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: University of Pennsylvania

Official(s) and/or principal investigator(s):
Steven M Kawut, MD, MS, Principal Investigator, Affiliation: University of Pennsylvania

Overall contact:
Tiffany Sharkoski, Phone: 215-746-4186, Email: sharkosk@exchange.upenn.edu

Summary

The main purpose of this clinical trial is to determine the safety and effects of the study drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood and the function of the lung vessels.

Clinical Details

Official title: Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Difference in changes in alveolar-arterial oxygen gradient between sorafenib and placebo groups

Secondary outcome:

Difference in changes in intrapulmonary shunting between sorafenib and placebo groups

Difference in changes in hematopoietic progenitor cells and other biomarker levels between sorafenib and placebo groups

Difference in changes in hematopoietic progenitor cells and other biomarker levels between sorafenib and placebo groups

Eligibility

Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of HPS:

1. AaPO2 ≥ 15 mm Hg (≥ 20 mm Hg for age > 64 yrs) 2. Intrapulmonary shunting 3. Absence of significant restriction (TLC < 70%) or obstruction (FEV1 < 80% & FEV1/FVC < 70%) 4. Presence of cirrhosis/hepatic fibrosis and/or portal hypertension

- Child-Pugh class A or B liver disease

- Platelet count ≥ 30 ×10e9 per liter

- Hemoglobin ≥ 8. 5 g per deciliter

- International normalized ratio ≤ 2. 3

- Albumin ≥ 2. 8 g per deciliter

- Total bilirubin ≤ 3 mg per deciliter

- Alanine aminotransferase and aspartate aminotransferase ≤ 5 times the upper limit of

the normal range

- Serum creatinine ≤ 1. 5 times the upper limit of the normal range and not receiving

dialysis

- Negative pregnancy test (for women of childbearing potential) at both screening and

baseline visits. Post-menopausal women (defined as no menses for one year) and surgically sterilized women are not required to undergo a pregnancy test.

- Subjects (men and women) of childbearing potential must agree to use medically

acceptable contraception beginning at the signing of the Informed Consent Form until at least 14 days after the last dose of study drug.

- Age ≥ 21 years

- Ability to provide informed consent

Exclusion Criteria:

- Recent chronic heavy alcohol consumption

- Enrollment in a clinical trial or concurrent use of another investigational drug or

device therapy (i. e., outside of study treatment) during, or within 28 days of screening visit

- Current hepatic encephalopathy

- Active infection

- Diagnosis of portopulmonary hypertension

- WHO Class IV functional status

- Congenital long-QT syndrome

- Subjects who have used strong CYP3A4 inducers (e. g., phenytoin, carbamazepine,

phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days before randomization

- Subjects who are currently taking Coumadin®(warfarin)

- Active or clinically significant cardiac disease, including:

1. Active coronary artery disease 2. Unstable angina (anginal symptoms at rest), new-onset angina within 12 weeks before randomization, or myocardial infarction within 24 weeks before randomization

- Liver or other solid organ transplant recipients

- Expectation of liver transplant within four months of randomization

- Hepatocellular carcinoma that does not meet all of the following criteria:

1. Single lesion ≤ 3 cm documented by LIRADS criteria 2. Complete response to ablative therapy (TACE, RFA, alcohol ablation) using the modified RECIST criteria one month after therapy with no more than two treatments 3. No other lesions develop after initiation of HCC therapy

- Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm

Hg on repeated measurement) despite optimal medical management.

- Any hemorrhage/bleeding event of NCI-Common Toxicity Criteria for Adverse Effects

v4. 0 Grade 3 or higher within 4 weeks before randomization

- Presence of a non-healing wound, non-healing ulcer, or bone fracture

- Women who are pregnant or breast-feeding

- Major surgery 28 days prior to randomization

- Subjects with any previously untreated or concurrent cancer except cervical cancer

in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before randomization are allowed. All cancer treatments (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) must be completed at least 3 years prior to study entry (i. e., signature date of the informed consent form).

- Inability to comply with the protocol and/or not willing or not available for

follow-up assessments

Locations and Contacts

Tiffany Sharkoski, Phone: 215-746-4186, Email: sharkosk@exchange.upenn.edu

Mayo Clinic, Rochester, Minnesota 55905, United States; Recruiting
Linda Stadheim, RN, Phone: 507-284-0141, Email: stadheim.linda@mayo.edu
Michael Krowka, MD, Principal Investigator

Columbia University-NewYork-Presbyterian Hospital, New York, New York 10032, United States; Recruiting
Samina Munir, Phone: 212-305-3839, Email: sm3417@cumc.columbia.edu
Robert Brown, MD, Principal Investigator

University of Pennsylvania - Perelman Center, Philadelphia, Pennsylvania 19104, United States; Recruiting
Tiffany Sharkoski, 15, Phone: 215-746-4186, Email: sharkosk@exchange.upenn.edu
Steven M Kawut, MD, MS, Principal Investigator
David Goldberg, MD, MSCE, Sub-Investigator

University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030, United States; Recruiting
Lacie Ford, Email: Lacie.L.Ford@uth.tmc.edu
Michael B Fallon, MD, Principal Investigator

Additional Information

Starting date: March 2014
Last updated: January 9, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017